These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 16616233)

  • 1. Valsartan improves resting skin blood flow in type 2 diabetic patients and reduces poly(adenosine diphosphate-ribose) polymerase activation.
    Shrikhande G; Khaodhiar L; Scali S; Lima C; Hubbard M; Dudley K; Ganda O; Ferran C; Veves A
    J Vasc Surg; 2006 Apr; 43(4):760-70; discussion 770-1. PubMed ID: 16616233
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The angiotensin II receptor antagonist valsartan inhibits endothelin 1-induced vasoconstriction in the skin microcirculation in humans in vivo: influence of the G-protein beta3 subunit (GNB3) C825T polymorphism.
    Mitchell A; Rushentsova U; Siffert W; Philipp T; Wenzel RR
    Clin Pharmacol Ther; 2006 Mar; 79(3):274-81. PubMed ID: 16513451
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension.
    Philipp T; Smith TR; Glazer R; Wernsing M; Yen J; Jin J; Schneider H; Pospiech R
    Clin Ther; 2007 Apr; 29(4):563-80. PubMed ID: 17617280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of the angiotensin II type 1 receptor antagonist valsartan on the expression of superoxide dismutase in hypertensive patients.
    Yang HY; Kao PF; Chen TH; Tomlinson B; Ko WC; Chan P
    J Clin Pharmacol; 2007 Mar; 47(3):397-403. PubMed ID: 17322151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.
    Ruilope LM; Malacco E; Khder Y; Kandra A; Bönner G; Heintz D
    Clin Ther; 2005 May; 27(5):578-87. PubMed ID: 15978306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure.
    Anand IS; Bishu K; Rector TS; Ishani A; Kuskowski MA; Cohn JN
    Circulation; 2009 Oct; 120(16):1577-84. PubMed ID: 19805651
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of valsartan on diabetic cardiomyopathy in rats with type 2 diabetes mellitus.
    Yang ZH; Peng XD
    Chin Med J (Engl); 2010 Dec; 123(24):3640-3. PubMed ID: 22166644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness and safety of high-dose valsartan monotherapy in hypertension treatment: the ValTop study.
    Parati G; Asmar R; Bilo G; Kandra A; Di Giovanni R; Mengden T
    Hypertens Res; 2010 Oct; 33(10):986-94. PubMed ID: 20686486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of valsartan on left ventricular anatomy and systolic function and aortic elasticity.
    Khaodhiar L; Brennan AM; Lima C; Chan JL; Mantzoros CS; Manning WJ; Danias PG; Veves A
    Metabolism; 2009 May; 58(5):682-8. PubMed ID: 19375592
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of valsartan and nifedipine coat-core on systemic arterial stiffness in hypertensive patients.
    Munakata M; Nagasaki A; Nunokawa T; Sakuma T; Kato H; Yoshinaga K; Toyota T
    Am J Hypertens; 2004 Nov; 17(11 Pt 1):1050-5. PubMed ID: 15533733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diuretic and enhanced sodium restriction results in improved antiproteinuric response to RAS blocking agents.
    Esnault VL; Ekhlas A; Delcroix C; Moutel MG; Nguyen JM
    J Am Soc Nephrol; 2005 Feb; 16(2):474-81. PubMed ID: 15615822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of valsartan on the progression of chronic renal insufficiency in patients with nondiabetic renal diseases.
    Ishimitsu T; Kameda T; Akashiba A; Takahashi T; Ando N; Ohta S; Yoshii M; Inada H; Tsukada K; Minami J; Ono H; Matsuoka H
    Hypertens Res; 2005 Nov; 28(11):865-70. PubMed ID: 16555574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of valsartan, an angiotensin II receptor antagonist, in hypertension after renal transplantation: a randomized multicenter study.
    Andrés A; Morales E; Morales JM; Bosch I; Campo C; Ruilope LM;
    Transplant Proc; 2006 Oct; 38(8):2419-23. PubMed ID: 17097955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of angiotensin II on pulse wave velocity in humans is mediated through angiotensin II type 1 (AT(1)) receptors.
    Rehman A; Rahman AR; Rasool AH
    J Hum Hypertens; 2002 Apr; 16(4):261-6. PubMed ID: 11967720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hong Kong study using valsartan in IgA nephropathy (HKVIN): a double-blind, randomized, placebo-controlled study.
    Li PK; Leung CB; Chow KM; Cheng YL; Fung SK; Mak SK; Tang AW; Wong TY; Yung CY; Yung JC; Yu AW; Szeto CC;
    Am J Kidney Dis; 2006 May; 47(5):751-60. PubMed ID: 16632013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardio-cerebrovascular protective effects of valsartan in high-risk hypertensive patients with coronary artery disease (from the Kyoto Heart Study).
    Shiraishi J; Sawada T; Koide M; Yamada H; Matsubara H;
    Am J Cardiol; 2012 May; 109(9):1308-14. PubMed ID: 22325086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of intensive blood pressure control with valsartan on urinary albumin excretion in normotensive patients with type 2 diabetes.
    Estacio RO; Coll JR; Tran ZV; Schrier RW
    Am J Hypertens; 2006 Dec; 19(12):1241-8. PubMed ID: 17161769
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of valsartan on the angiotensin II pressor response in healthy normotensive male subjects.
    Morgan JM; Palmisano M; Piraino A; Hirschhorn W; Spencer S; Prasad PP; Ortiz M; Lloyd P
    Clin Pharmacol Ther; 1997 Jan; 61(1):35-44. PubMed ID: 9024172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beneficial effects of valsartan in asymptomatic individuals with vascular or cardiac abnormalities: the DETECTIV Pilot Study.
    Duprez DA; Florea ND; Jones K; Cohn JN
    J Am Coll Cardiol; 2007 Aug; 50(9):835-9. PubMed ID: 17719468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of valsartan, an angiotensin II receptor blocker, on markers of oxidation and glycation in Japanese type 2 diabetic subjects: blood pressure-independent effect of valsartan.
    Saisho Y; Komiya N; Hirose H
    Diabetes Res Clin Pract; 2006 Nov; 74(2):201-3. PubMed ID: 16737758
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.